The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis

被引：13

作者：

Herfarth, Hans ^{[1
]}

机构：

[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA

来源：

DIGESTIVE DISEASES | 2012年 / 30卷

关键词：

Anti-inflammatory agents; Non-steroidal/therapeutic use; Mesalamine; Colorectal cancer; Ulcerative colitis; Crohn's disease; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; RISK-FACTORS; RANDOMIZED-TRIAL; NEOPLASIA; MESALAZINE; DYSPLASIA; THERAPY; PREVENT; ACID; ADENOMAS;

D O I：

10.1159/000341894

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

5-aminosalicylates (5-ASA) are widely used to treat patients with ulcerative colitis. Experimental data suggest that these agents can potentially be used in a chemopreventive fashion to inhibit the development of colitis-associated colorectal cancer (CRC); however, observational studies investigating a possible risk reduction of CRC by 5-ASA therapy have revealed conflicting results. Currently, it appears that 5-ASA have no or only a very limited effect as a deterrence against CRC. Thus, a general recommendation for long-term use of 5-ASA solely for chemopreventive measures is not warranted. Copyright (c) 2012 S. Karger AG, Basel

引用

页码：55 / 59

页数：5

共 50 条

[21] The role of aminosalicylates in the treatment of ulcerative colitis
Van Assche, G
Baert, F
De Reuck, M
De Vos, M
De Wit, O
Hoang, P
Louis, E
Mana, F
Pelckmans, P
Rutgeerts, P
Van Gossum, A
D'Haens, G
ACTA GASTRO-ENTEROLOGICA BELGICA, 2002, 65 (04) : 196 - 199
[22] DOES SWITCHING BETWEEN 5-AMINOSALICYLATES AFFECT THIOPURINE METABOLISM AND CLINICAL OUTCOMES IN PATIENT WITH ULCERATIVE COLITIS?
Morikubo, Hiromu
Ozaki, Ryo
Okabayashi, Shinji
Kiyohara, Hiroki
Matsubayashi, Mao
Sagami, Shintaro
Nakano, Masaru
Ikezaki, Osamu
Hisamatsu, Tadakazu
Hibi, Toshifumi
Kobayashi, Taku
GASTROENTEROLOGY, 2019, 156 (06) : S1144 - S1144
[23] Prevention of colorectal cancer in inflammatory bowel disease: Value of screening and 5-aminosalicylates
Munkholm, P
Loftus, EV
Reinacher-Schick, A
Kornbluth, A
Mittmann, U
Esendal, B
DIGESTION, 2006, 73 (01) : 11 - 19
[24] Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein, CN
Blanchard, JF
Metge, C
Yogendran, M
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12): : 2784 - 2788
[25] Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes
Limketkai, B.
Ungaro, R.
Jess, T.
Allin, K.
Agrawal, M.
Ullman, T.
Colombel, J. -F.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S287 - S288
[26] The Prevention of Colitis-Related Cancer by 5-Aminosalicylates: An Appealing Hypothesis that Remains Unproven
Terdiman, Jonathan P.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04): : 737 - 740
[27] Chemoprevention: a new way to face colorectal cancer in ulcerative colitis
Biasco, G
Zannoni, U
ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 30 (04): : 426 - 427
[28] Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein, CN
Metge, C
Blanchard, JF
Yogendran, M
GASTROENTEROLOGY, 2003, 124 (04) : A36 - A36
[29] No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy
Singh, Siddharth
Kim, Jihoon
Zhu, Wenhong
Dulai, Parambir S.
Sandborn, William J.
Jairath, Vipul
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (03) : 481 - 491
[30] A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis
Shekoufeh Nikfar
Roja Rahimi
Ali Rezaie
Mohammad Abdollahi
Digestive Diseases and Sciences, 2009, 54 : 1157 - 1170

← 1 2 3 4 5 →